Genmab beats Q1 expectations and narrows full-year guidance range
The Danish biotech company had a strong first quarter and has increased its minimum revenue guidance for 2022.
by andreas lønstrup, translated by catherine brett
Genmab ended Q1, 2022 with a revenue of DKK 2.1bn (USD 300m) compared to DKK 1.6bn (USD 230m) for the same period last year. The biotech company also reported an EBIT (earnings before interest and taxes) result of DKK 514m (USD 72.7m) compared to DKK 532m (USD 75m) for Q1, 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab enters agreement on cancer biomarker
For subscribers
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers
